Alpha-1 HC

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Cystic FibrosisEmphysema

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

1

Alpha-1 HC

Grifols Therapeutics LLC

Phase 3

12

Calciferol

Alnylam Pharmaceuticals

Preclinical

13

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

34

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

25

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

26

Aztreonam Lysine

Gilead

Preclinical

57

Advil

KKenvue Brands

Preclinical

18

Tums

Otsuka

Preclinical

19

Feosol

AAuerbach Hematology Oncology Associates P C

Preclinical

110

Capromorelin

UUniversity of Aarhus

Preclinical

1Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Alpha-1 Antitrypsin Deficiency2 trials

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

Completed·Grifols Therapeutics LLC·Phase 1/2·NCT02870309·4 enrolled

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Completed·Grifols Therapeutics LLC·Phase 1/2·NCT04722887·17 enrolled

Adult1 trial

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

Completed·Grifols Therapeutics LLC·Phase 3·NCT00295061·24 enrolled

Cystic Fibrosis1 trial

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Completed·Grifols Therapeutics LLC·Phase 2·NCT01684410·30 enrolled

ESS1 trial

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

Completed·Grifols Therapeutics LLC·Phase 3·NCT00301366·38 enrolled

Pulmonary Emphysema in Alpha-1 PI Deficiency1 trial

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency

Active, not recruiting·Grifols Therapeutics LLC·Phase 3·NCT01983241·345 enrolled

2 more indications

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency1 trial

An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency

Enrolling by invitation·Grifols Therapeutics LLC·Phase 3·NCT02796937·290 enrolled

Unspecified1 trial

Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

Completed·Grifols Therapeutics LLC·Phase 1/2·NCT02870348·4 enrolled

Details

Drug Info

Related News